Revolutionising point-of-care molecular diagnostics with a sub 10 minute PCR test

Polymerase chain reaction (PCR) tests are one of the most popular diagnostic tools for the detection and diagnosis of viral diseases, such as coronavirus (COVID-19), due to their ability to rapidly and accurately deliver results for guidance on treatment.

The global impact of the COVID-19 pandemic has sparked a renewed interest in molecular diagnostics, leading to an increased need for innovative testing alternatives. This demand has paved the way for the expansion of point-of-care (POC) testing options, leveraging advanced next-generation technologies that significantly reduce sample-to-answer turnaround times.

Advantages of point-of-care testing

Broadly speaking, point-of-care (POC) testing allows clinicians and patients to obtain diagnostic results at the point of use and, if the test is quick enough, during just one appointment. Where PCR is used in a POC device, this enables fast, accurate results to help inform timely treatment options for patients, even if they are asymptomatic. 

The use of economical and portable POC devices can alleviate the workload in laboratories, general practitioner surgeries, and hospitals, while simultaneously boosting patient screening capacities. This, in turn, contributes to slowing the transmission of diseases by enabling efficient and widespread screening measures.

Technical challenges 

Lateral flow devices, commonly used during the COVID-19 pandemic for rapid antigen testing, lack the sensitivity of lab-based PCR testing. The development of PCR-based POC testing for diseases like influenza and COVID-19 has the potential to significantly enhance patient outcomes and operational efficiencies. However, several technical challenges impede progress in this area.

  • POC diagnostic test devices require portability and room temperature storage compatibility for use in GP surgeries and pharmacies.
  • The reagents must perform multiple functions, including allowing viral extraction from a nasal swab while preserving lysed RNA to maintain high test sensitivity during RT-PCR.
  • Reagents need to also exhibit advanced tolerance to diverse specimen inhibition, enabling amplification in the presence of non-target DNA and PCR inhibitors like cellular debris and proteins.
  • Storage at room temperature is supported by lyophilization of the RT-PCR reagents, presenting a further challenge concerning fast and efficient rehydration of reagents, that need to be incorporated into an automated workflow.
  • PCR-based POC tests must support rapid thermocycling to enable quick amplification of multiple targets at significantly faster speeds than current technologies.
  • It is vital that whilst addressing these challenges, the test is economical and scalable to make it deliverable in care environments.

Find out how working with LGC Biosearch Technologies, the team at LEX Diagnostics developed a customised RT-PCR master mix suitable for the unique demands of fast, sensitive POC PCR testing, successfully solving the technical challenges they faced. 

Download the full case study

About LGC Biosearch Technologies 

Together, we help you advance.

Whether you’re using marker-assisted selection to develop more nutritious and sustainable crops or developing the next generation of molecular diagnostic tests, clinical genomics assays, or novel oligo therapeutics, accurate and high-quality data is everything. And so is speed.

To help keep your mission-critical projects on target and moving quickly, LGC provides a large integrated portfolio of products and services to support your entire genomics workflow and help at every stage of your product development pipeline. From R&D through to large-scale commercialization, our products and services scale up when you do.

Watch the video to see how our unified genomics portfolio helps you discover more, speeding up your work to improve the human condition.


Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: Jun 29, 2023 at 8:36 AM

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    LGC Biosearch Technologies. (2023, June 29). Revolutionising point-of-care molecular diagnostics with a sub 10 minute PCR test. News-Medical. Retrieved on October 08, 2024 from https://www.news-medical.net/whitepaper/20230628/How-LEX-Diagnostics-and-LGC-Biosearch-enable-the-next-generation-of-point-of-care-diagnostics.aspx.

  • MLA

    LGC Biosearch Technologies. "Revolutionising point-of-care molecular diagnostics with a sub 10 minute PCR test". News-Medical. 08 October 2024. <https://www.news-medical.net/whitepaper/20230628/How-LEX-Diagnostics-and-LGC-Biosearch-enable-the-next-generation-of-point-of-care-diagnostics.aspx>.

  • Chicago

    LGC Biosearch Technologies. "Revolutionising point-of-care molecular diagnostics with a sub 10 minute PCR test". News-Medical. https://www.news-medical.net/whitepaper/20230628/How-LEX-Diagnostics-and-LGC-Biosearch-enable-the-next-generation-of-point-of-care-diagnostics.aspx. (accessed October 08, 2024).

  • Harvard

    LGC Biosearch Technologies. 2023. Revolutionising point-of-care molecular diagnostics with a sub 10 minute PCR test. News-Medical, viewed 08 October 2024, https://www.news-medical.net/whitepaper/20230628/How-LEX-Diagnostics-and-LGC-Biosearch-enable-the-next-generation-of-point-of-care-diagnostics.aspx.

Other White Papers by this Supplier

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.